JPH05502581A - 付着的に結合した細胞を有するマトリックスおよびウイルス/ウイルス抗原の製造方法 - Google Patents
付着的に結合した細胞を有するマトリックスおよびウイルス/ウイルス抗原の製造方法Info
- Publication number
- JPH05502581A JPH05502581A JP3501132A JP50113291A JPH05502581A JP H05502581 A JPH05502581 A JP H05502581A JP 3501132 A JP3501132 A JP 3501132A JP 50113291 A JP50113291 A JP 50113291A JP H05502581 A JPH05502581 A JP H05502581A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- virus
- matrix
- antigen
- tbe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims description 71
- 239000000427 antigen Substances 0.000 title claims description 56
- 102000036639 antigens Human genes 0.000 title claims description 56
- 108091007433 antigens Proteins 0.000 title claims description 56
- 238000004519 manufacturing process Methods 0.000 title claims description 38
- 230000003612 virological effect Effects 0.000 title claims description 33
- 210000004027 cell Anatomy 0.000 claims description 82
- 239000011159 matrix material Substances 0.000 claims description 31
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 239000002609 medium Substances 0.000 claims description 13
- 230000010412 perfusion Effects 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 5
- 210000004102 animal cell Anatomy 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 230000005727 virus proliferation Effects 0.000 claims description 2
- 241000238876 Acari Species 0.000 claims 1
- 241000712891 Arenavirus Species 0.000 claims 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims 1
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 229920002994 synthetic fiber Polymers 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 13
- 238000004113 cell culture Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (12)
- 1.ウイルスに感染したヒトまたは動物細胞が付着的に結合しているウイルス/ ウイルス抗原製造のためのマトリックス。
- 2.付着的に結合している細胞としてVero細胞ATCC CCL81が用い られていることを特徴とする請求項1のマトリックス。
- 3.付着的に結合している細胞がダニによって媒介される脳炎(TBE)ウイル スに感染していることを特徴とする請求項1または2のマトリックス。
- 4.付着的に結合している細胞がフラビウイスルまたはアレナウイルスに感染し ていることを特徴とする請求項1または2のマトリックス。
- 5.ガラス、交差結合デキストラン、ゼラチンまたは合成物質からなることを特 徴とする請求項1〜4のいずれかに記載のマトリックス。
- 6.マイクロキャリアーとして設計されていることを特徴とする請求項5のマト リックス。
- 7.その表面1cm2あたり1x105−4x105個の細胞が付着的に結合し ていることを特徴とする請求項1〜6のいずれか1項、またはそれ以上に記載の マトリックス。
- 8.請求項1〜3または5〜7のいずれかに記載のマトリックスを用いるダニに 媒介される脳炎(TBE)ウイルス抗原の製造方法であって、表面依存性永久細 胞、好ましくはVero細胞ATCCCCL81にTBEウイルスを接種し、細 胞を、細胞内での抗原の生成が維持され抗原が培地に分泌されるよう、生存性を 保ちながら、血清不含培地中のマトリックスに付着的に結合させたまま維持し、 そこで抗原含有培地を担体−結合細胞から分離し、製剤的に許容される既知の方 法で濃縮、不活化および精製により処理することを特徴とする方法。
- 9.ウイルス増殖および抗原生成を連続的に操作される灌流反応装置で少なくと も5日間、34〜37℃の温度で行うことを特徴とする請求項8の方法。
- 10.灌流を灌流速度0.3−10v/v/日で行うことを特徴とする請求項9 の方法。
- 11.灌流リアクター内で、発酵容量1Lあたり、2x109−2x1010細 胞の細胞密度(後者は連続フローファーメンターによる)が得られることを特徴 とする請求項9の方法。
- 12.培地内の抗原濃度1−10μg/mlが維持されることを特徴とする請求 項8〜11のいずれか1項または数項の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT2928/89A AT393356B (de) | 1989-12-22 | 1989-12-22 | Verfahren zur herstellung von fsme-virus-antigen |
AT2928/89 | 1989-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05502581A true JPH05502581A (ja) | 1993-05-13 |
JP2633391B2 JP2633391B2 (ja) | 1997-07-23 |
Family
ID=3542524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50113291A Expired - Fee Related JP2633391B2 (ja) | 1989-12-22 | 1990-12-21 | 付着的に結合した細胞を有するマトリックスおよびウイルス/ウイルス抗原の製造方法 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0506714B1 (ja) |
JP (1) | JP2633391B2 (ja) |
AT (2) | AT393356B (ja) |
CA (1) | CA2071954C (ja) |
CZ (1) | CZ281804B6 (ja) |
DE (1) | DE59007659D1 (ja) |
DK (1) | DK0506714T3 (ja) |
ES (1) | ES2067916T3 (ja) |
FI (1) | FI98377C (ja) |
HR (1) | HRP921354A2 (ja) |
HU (1) | HU213886B (ja) |
NO (1) | NO310305B1 (ja) |
RU (1) | RU2082757C1 (ja) |
SK (1) | SK659090A3 (ja) |
WO (1) | WO1991009935A1 (ja) |
YU (1) | YU242390A (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020565A1 (fr) * | 1998-10-05 | 2000-04-13 | The Research Foundation For Microbial Diseases Of Osaka University | Immunogene ameliore pour un vaccin inactive contre une infection a virus de l'encephalite japonaise et procede de production associe |
WO2005014803A1 (ja) * | 2003-08-07 | 2005-02-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 西ナイルウイルスワクチン |
JP2014100148A (ja) * | 2007-12-27 | 2014-06-05 | Baxter Internatl Inc | 細胞培養プロセス |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2290053A1 (en) * | 1994-11-10 | 2011-03-02 | Baxter Healthcare S.A. | Method for producing Influenza virus in protein-free cell culture medium |
US6149917A (en) * | 1995-08-01 | 2000-11-21 | Pasteur Merieux Serums Et Vaccins | Industrial production process for a vaccine against Japanese encephalitis virus and vaccine produced |
FR2737412B1 (fr) * | 1995-08-01 | 1997-10-24 | Pasteur Merieux Serums Vacc | Procede de production d'un vaccin contre le virus de l'encephalite japonaise et vaccin obtenu par ce procede |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
US6951752B2 (en) * | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
US6855535B2 (en) * | 2001-12-10 | 2005-02-15 | Baxter Healthcare S.A. | Method of large scale production of Hepatitis A virus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT358167B (de) * | 1978-12-22 | 1980-08-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- -meningoenzephalitis-virus (fsme-virus)- -vakzinen |
SE445116B (sv) * | 1979-09-12 | 1986-06-02 | Pharmacia Fine Chemicals Ab | Sett att odla celler pa mikroberare med fibronektinytskikt |
NO161446C (no) * | 1981-03-13 | 1989-08-16 | Damon Biotech Inc | Fremgangsmaate for dyrking av celler som er avhengige av forankring. |
SE8103138L (sv) * | 1981-05-19 | 1982-11-20 | Pharmacia Fine Chemicals Ab | Mikroberare for odling av forankringsberoende celler |
CA1206900A (en) * | 1981-12-21 | 1986-07-02 | Raymond L. Downs | Hollow glass shell microcarrier for growth of cell cultures, and method of shell manufacture |
AT385203B (de) * | 1985-04-26 | 1988-03-10 | Immuno Ag | Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine |
DD274336A3 (de) * | 1985-10-03 | 1989-12-20 | Npo Biolar | Verfahren zur Gewinnung einer Mikroträgersubstanz für die Zellkultivierung |
-
1989
- 1989-12-22 AT AT2928/89A patent/AT393356B/de not_active IP Right Cessation
-
1990
- 1990-12-21 CA CA 2071954 patent/CA2071954C/en not_active Expired - Lifetime
- 1990-12-21 HU HU9202009A patent/HU213886B/hu unknown
- 1990-12-21 AT AT91900666T patent/ATE113652T1/de not_active IP Right Cessation
- 1990-12-21 ES ES91900666T patent/ES2067916T3/es not_active Expired - Lifetime
- 1990-12-21 YU YU242390A patent/YU242390A/sh unknown
- 1990-12-21 WO PCT/AT1990/000128 patent/WO1991009935A1/de active IP Right Grant
- 1990-12-21 DE DE59007659T patent/DE59007659D1/de not_active Expired - Fee Related
- 1990-12-21 CZ CS906590A patent/CZ281804B6/cs not_active IP Right Cessation
- 1990-12-21 EP EP19910900666 patent/EP0506714B1/de not_active Expired - Lifetime
- 1990-12-21 SK SK6590-90A patent/SK659090A3/sk not_active IP Right Cessation
- 1990-12-21 JP JP50113291A patent/JP2633391B2/ja not_active Expired - Fee Related
- 1990-12-21 RU SU905052769A patent/RU2082757C1/ru not_active IP Right Cessation
- 1990-12-21 DK DK91900666T patent/DK0506714T3/da not_active Application Discontinuation
-
1992
- 1992-06-18 FI FI922851A patent/FI98377C/fi active
- 1992-06-19 NO NO19922422A patent/NO310305B1/no not_active IP Right Cessation
- 1992-11-25 HR HRP921354 patent/HRP921354A2/xx not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020565A1 (fr) * | 1998-10-05 | 2000-04-13 | The Research Foundation For Microbial Diseases Of Osaka University | Immunogene ameliore pour un vaccin inactive contre une infection a virus de l'encephalite japonaise et procede de production associe |
WO2005014803A1 (ja) * | 2003-08-07 | 2005-02-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 西ナイルウイルスワクチン |
JP2014100148A (ja) * | 2007-12-27 | 2014-06-05 | Baxter Internatl Inc | 細胞培養プロセス |
Also Published As
Publication number | Publication date |
---|---|
DK0506714T3 (da) | 1995-04-18 |
FI922851A (fi) | 1992-06-18 |
CZ659090A3 (en) | 1996-11-13 |
ATE113652T1 (de) | 1994-11-15 |
HRP921354A2 (en) | 1996-02-29 |
AT393356B (de) | 1991-10-10 |
JP2633391B2 (ja) | 1997-07-23 |
WO1991009935A1 (de) | 1991-07-11 |
CA2071954A1 (en) | 1991-06-23 |
FI922851A0 (fi) | 1992-06-18 |
DE59007659D1 (de) | 1994-12-08 |
SK279236B6 (sk) | 1998-08-05 |
YU242390A (sh) | 1993-05-28 |
CA2071954C (en) | 1996-06-18 |
ATA292889A (de) | 1991-03-15 |
RU2082757C1 (ru) | 1997-06-27 |
EP0506714B1 (de) | 1994-11-02 |
HU213886B (en) | 1997-11-28 |
NO310305B1 (no) | 2001-06-18 |
EP0506714A1 (de) | 1992-10-07 |
SK659090A3 (en) | 1998-08-05 |
FI98377B (fi) | 1997-02-28 |
HU9202009D0 (en) | 1992-10-28 |
FI98377C (fi) | 1997-06-10 |
HUT65410A (en) | 1994-06-28 |
ES2067916T3 (es) | 1995-04-01 |
NO922422L (no) | 1992-08-17 |
NO922422D0 (no) | 1992-06-19 |
CZ281804B6 (cs) | 1997-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Giard et al. | Virus production with a newly developed microcarrier system | |
JP2633392B2 (ja) | ウイルス/ウイルス抗原を生産するためのバイオマス | |
EP2075005B1 (en) | Ipv-dpt vaccine | |
JP2633391B2 (ja) | 付着的に結合した細胞を有するマトリックスおよびウイルス/ウイルス抗原の製造方法 | |
Danner et al. | In vitro studies on Borna virus: I. The use of cell cultures for the demonstration, titration and production of Borna virus | |
US5719051A (en) | Perfusion system and a method for the large scale production of virus or virus antigen | |
Matsumoto et al. | Further studies on the replication of rabies and rabies-like viruses in organized cultures of mammalian neural tissues | |
US3935066A (en) | Cell lines | |
Goldberg et al. | Susceptibility of differentiating muscle cells of the fetal mouse in culture to coxsackievirus A13 | |
IE47060B1 (en) | Process for the cultivation of viruses | |
CA2769003A1 (en) | Drain down and re-feed of microcarrier bioreactor | |
Nicholson | Growth of fish cell lines on microcarriers | |
Bradley et al. | Transformation of African green monkey kidney cells with the RF strain of human papovarivus BKVB | |
US3228840A (en) | Virus culture | |
NO860180L (ja) | ||
Mifune et al. | Susceptibility of various cell lines to rabies virus | |
Trowbridge | Long-term visna virus infection of sheep choroid plexus cells: initiation and preliminary characterization of the carrier cultures | |
OSTER‐GRANITE et al. | STUDIES OF CULTURED HUMAN AND SIMIAN FETAL BRAIN CELLS: II. INFECTIONS WITH HUMAN (BK) AND SIMIAN (SV40) PAPOVAVIRUSES | |
Fabry et al. | High density microcarrier cell culture for viral vaccine production. | |
RU2076905C1 (ru) | Способ суспензионного культивирования филовирусов в клеточных культурах на микроносителях | |
JPS61158798A (ja) | B型肝炎ウイルス表面抗原の製造法 | |
KR960013438B1 (ko) | 신규한 신증후 출혈열 백신의 제조방법 및 그로부터 제조된 백신 | |
Thomson et al. | Growth of rubella virus in a glass bead propagator | |
Yu et al. | Reproduction of Strain Sof'in Forest-Spring Encephalitis in Vero Cell Line Cultured on Microcarrier under Pseudo-submerged Conditions | |
NO751303L (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080109 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090109 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100109 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090425 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100425 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
LAPS | Cancellation because of no payment of annual fees |